Page 18 - பெரெல்லா வெயின்பெர்க் கூட்டாளர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article MINNEAPOLIS and AUSTIN, Texas, March 3, 2021  /PRNewswire/ Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Asuragen, Inc. for initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.  The transaction will be financed through a combination of cash on hand and an existing revolving line of credit.  Bio-Techne anticipates the acquisition to close in the fourth quarter of its fiscal 2021. Founded in 2006, Asuragen is headquartered in Austin, Texas and is a leader in the development, manufacturing and commercialization of genetic carrier screening and oncology testing kits.  Asuragen s products leverage proprietary chemistries which can be used on widely available platforms

United statesChuck kummethDavid clairFredrickson byronLynne hohlfeldMatt mcmanusExchange commissionPrnewswire bio techne corporationAmerican college of obstetriciansCorporate developmentAsuragen incVinson elkinsBio techne corporationTechne corporationGood manufacturing practiceChief executive officer